Scientific Reports (Mar 2024)

Host metabolomic responses in recurrent P. vivax malaria

  • Michael N. Yakubu,
  • Victor I. Mwangi,
  • Rebeca L. A. Netto,
  • Maria G. C. Alecrim,
  • Jessica R. S. Alves,
  • Anne C. G. Almeida,
  • Gabriel F. Santos,
  • Gesiane S. Lima,
  • Lucas S. Machado,
  • Hector H. F. Koolen,
  • Tiago P. Guimarães,
  • Andrea R. Chaves,
  • Boniek G. Vaz,
  • Wuelton M. Monteiro,
  • Fabio T. M. Costa,
  • Marcus V. G. Lacerda,
  • Luiz G. Gardinassi,
  • Gisely C. de Melo

DOI
https://doi.org/10.1038/s41598-024-54231-5
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Malaria is the leading parasitic disease worldwide, with P. vivax being a major challenge for its control. Several studies have indicated metabolomics as a promising tool for combating the disease. The study evaluated plasma metabolomic profiles of patients with recurrent and non-recurrent P. vivax malaria in the Brazilian Amazon. Metabolites extracted from the plasma of P. vivax-infected patients were subjected to LC–MS analysis. Untargeted metabolomics was applied to investigate the metabolic profile of the plasma in the two groups. Overall, 51 recurrent and 59 non-recurrent patients were included in the study. Longitudinal metabolomic analysis revealed 52 and 37 significant metabolite features from the recurrent and non-recurrent participants, respectively. Recurrence was associated with disturbances in eicosanoid metabolism. Comparison between groups suggest alterations in vitamin B6 (pyridoxine) metabolism, tyrosine metabolism, 3-oxo-10-octadecatrienoate β-oxidation, and alkaloid biosynthesis II. Integrative network analysis revealed enrichment of other metabolic pathways for the recurrent phenotype, including the butanoate metabolism, aspartate and asparagine metabolism, and N-glycan biosynthesis. The metabolites and metabolic pathways predicted in our study suggest potential biomarkers of recurrence and provide insights into targets for antimalarial development against P. vivax.